Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (SNDX) has granted inducement awards to seven new employees under its 2023 Inducement Plan. The awards consist of options to purchase up to 188,100 shares of common stock. The stock options have a four-year vesting schedule, with 25% of shares vesting after one year and the remaining 1/48th vesting monthly over the subsequent 36 months, contingent on continued employment with Syndax.
Syndax Pharmaceuticals (SNDX) ha assegnato premi di incentivo a sette nuovi dipendenti nell'ambito del suo Piano di Incentivazione 2023. I premi consistono in opzioni per l'acquisto di fino a 188.100 azioni ordinarie. Le stock option prevedono un periodo di maturazione di quattro anni, con il 25% delle azioni che maturano dopo un anno e il restante 1/48 che matura mensilmente nei successivi 36 mesi, a condizione che il rapporto di lavoro con Syndax continui.
Syndax Pharmaceuticals (SNDX) ha otorgado premios de inducción a siete nuevos empleados bajo su Plan de Inducción 2023. Los premios consisten en opciones para comprar hasta 188,100 acciones comunes. Las opciones sobre acciones tienen un calendario de adquisición de derechos de cuatro años, con el 25% de las acciones adquiridas después de un año y el restante 1/48 adquirido mensualmente durante los siguientes 36 meses, condicionado a la continuidad del empleo con Syndax.
Syndax Pharmaceuticals (SNDX)는 2023년 유인 계획에 따라 7명의 신입 직원에게 유인 보상을 부여했습니다. 이 보상은 최대 188,100주의 보통주를 매수할 수 있는 옵션으로 구성되어 있습니다. 스톡 옵션은 4년간의 베스팅 일정이 있으며, 25%는 1년 후에 베스팅되고 나머지 1/48은 이후 36개월 동안 매월 베스팅되며, Syndax에서 계속 근무하는 경우에 한합니다.
Syndax Pharmaceuticals (SNDX) a accordé des primes d'incitation à sept nouveaux employés dans le cadre de son Plan d'Incitation 2023. Ces primes consistent en des options d'achat pouvant atteindre 188 100 actions ordinaires. Les options d'achat d'actions suivent un calendrier d'acquisition de quatre ans, avec 25% des actions acquises après un an et le reste à raison de 1/48 chaque mois pendant les 36 mois suivants, sous réserve de la poursuite de l'emploi chez Syndax.
Syndax Pharmaceuticals (SNDX) hat sieben neuen Mitarbeitern im Rahmen seines Inducement-Plans 2023 Anreizprämien gewährt. Die Prämien bestehen aus Optionen zum Kauf von bis zu 188.100 Aktien des Stammkapitals. Die Aktienoptionen haben einen vierjährigen Vesting-Zeitplan, wobei 25% der Aktien nach einem Jahr vesten und die restlichen 1/48 monatlich über die folgenden 36 Monate vesten, vorausgesetzt, die Beschäftigung bei Syndax wird fortgesetzt.
- None.
- None.
NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2025 the Company granted inducement awards to purchase up to 188,100 shares of common stock to seven new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
FAQ
What type of inducement awards did Syndax Pharmaceuticals (SNDX) grant in May 2025?
How many employees received inducement grants from SNDX in May 2025?
What is the vesting schedule for SNDX's May 2025 inducement stock options?
When did Syndax Pharmaceuticals (SNDX) grant the inducement awards?
